BB's Stock Haven

[libertyhound]

Successful Parkinson's Disease P-2 trial.

http://finance.yahoo.com/news/Neurologix-Announces-prnews-2701823243.html?x=0&.v=1

25 million share float, small biotech with gene therapy treatment for Parkinson's Disease. Cash appears down to 9 months, so some type of capital raise can be expected. Specifics of response in treatment arm apparently will have to await journal publication.

"Press Release Source: Neurologix, Inc. On Tuesday June 22, 2010, 8:30 am EDT"

Excerpt:

"FORT LEE, N.J., June 22 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board:NRGX.ob - News), today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease (PD), NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery. In the trial, this benefit was seen at one month and continued virtually unchanged throughout the six month blinded study period. The results also demonstrated a positive safety profile for NLX-P101, with no serious adverse events related to the gene therapy or surgical procedure reported. Patients enrolled in the trial had moderate to advanced PD and were not adequately responsive to current therapies."

This study was for poorly responsive severe Parkinson's, but once results are validated in P-3, sky is the limit as there were no serious adverse events associated with treatment. Assuming the PR is accurate and the response is durable, this could be another DNDN or HGSI.